Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-blind Randomized Controlled Trial of 10 mcg HXP-GPOVac Vaccine in Healthy Volunteers
TCTR20220804007Phase 2Completed
- Sponsor
- Government Pharmaceutical Organization
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant NDV vectored vaccine for SARS-CoV-2 in coronavirus disease 2019 (COVID-19), sponsored by Government Pharmaceutical Organization. Started Aug 2022; status: completed.
02
Drugs
recombinant NDV vectored vaccine for SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220804007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220804007.